Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received the second dose of SHINGRIX 1 2 years after the first dose; wiped them for a day; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of fatigue in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced fatigue (Verbatim: wiped them for a day) and drug dose administration interval too long (Verbatim: received the second dose of SHINGRIX 1 2 years after the first dose). The outcome of the fatigue was resolved (duration 1 day) and the outcome of the drug dose administration interval too long was not applicable. It was unknown if the reporter considered the fatigue and drug dose administration interval too long to be related to Shingrix. It was unknown if the company considered the fatigue and drug dose administration interval too long to be related to Shingrix. Additional Information: GSK Receipt Date: 14-OCT-2025 The patient reported that they received the second dose of Shingrix 1 to 2 years after the first dose worthwhile just to avoid shingles. The patient reported that the first dose wiped them for a day or so second did not. The batch number was not provided, and we are unable to contact the reporter. This case was reported by a patient via interactive digital media.